

ARNOLD
WHITE &
DURKEE
A PROFESSIONAL CORPORATION
ATTORNEYS AT LAW

Austin
Chicago
Houston
Menlo Park
Minneapolis
Washington



July 23, 1999



RECEIVED
AUG 02 1999

TECH CENTER 1600/2900

FILE: UTXC:504

RECEIVED

JUL 10 2002

CERTIFICATE OF MAILING
37 C.F.R. 1.8

TECH CENTER 1600/2900

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231, on the date below:

July 23, 1999

Date

David L. Parker

Assistant Commissioner for Patents
Washington, DC 20231

RE: *SN 08/726,211 "INHIBITION OF BCL-2 PROTEIN EXPRESSION BY LIPIDOMAL ANTISENSE OLIGODEOXYNUCLEOTIDES" Mar Tarmo et al.*
(UTMDACC:504)

Sir:

Enclosed for filing in the above-referenced patent application is a Supplemental Information Disclosure Statement, PTO-Form 1449 and references (A14-A36; E6-B17 and C95-C134).

A fee as set forth in 37 C.F.R. § 1.17(p) in the amount of \$240.00 is enclosed herewith. If an appropriate check has not been enclosed, or if it is insufficient, the Assistant Commissioner is hereby authorized to deduct any necessary fees from Arnold, White & Durkee Deposit Account No. 01-2508/ UTXC:504/PAR.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

David L. Parker
Reg. No. 32,165

DLP/pds
Encl:

BEST AVAILABLE COPY

RECEIVED

JUL 10 2002

TECH CENTER 1600/2900

RECEIVED
AUG 02 1999

TECH CENTER 1600/2900



CERTIFICATE OF MAILING
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date below:

July 23, 1999

Date

David L. Parker

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Mar Tormo
Ana M. Tari
Gabriel Lopez-Berestein

Serial No.: 08/726,211

Filed: October 4, 1996

For: INHIBITION OF BCL-2 PROTEIN
EXPRESSION BY LIPOSOMAL
ANTISENSE
OLIGODEOXYNUCLEOTIDES

Group Art Unit: 1805

Examiner: Schwartzman, R.

Atty. Dkt. No.: UTXC:504/PAR

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.


In accordance with 37 C.F.R. §§ 1.97(c)2, this Supplemental Information Disclosure Statement is being filed prior to the mailing date of the Final Official Action or Notice of Allowance. A fee

240.00
0000065 0872621
07/30/1999 MHAPP
01 FC:126

as set forth in 37 C.F.R. § 1.17(p) in the amount of \$240.00 is enclosed herewith. If an appropriate check has not been enclosed, or if it is insufficient, the Assistant Commissioner is hereby authorized to deduct said fee from Arnold, White & Durkee Deposit Account No. 01-2508/UTXC:504---/PAR.

Pursuant to 37 C.F.R §§ 1.97(g),(h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

Applicant respectfully requests that the listed documents be made of record in the present case.

Respectfully submitted,


David L. Parker
Reg. No. 32,165
Attorney for Applicant

ARNOLD, WHITE & DURKEE
P.O. Box 4433
Houston, Texas 77210-4433
(512) 418-3000

Date: July 23, 1999